Cargando…

Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy

BACKGROUND: Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sápi, Johanna, Kovács, Levente, Drexler, Dániel András, Kocsis, Pál, Gajári, Dávid, Sápi, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635016/
https://www.ncbi.nlm.nih.gov/pubmed/26540189
http://dx.doi.org/10.1371/journal.pone.0142190
_version_ 1782399460570038272
author Sápi, Johanna
Kovács, Levente
Drexler, Dániel András
Kocsis, Pál
Gajári, Dávid
Sápi, Zoltán
author_facet Sápi, Johanna
Kovács, Levente
Drexler, Dániel András
Kocsis, Pál
Gajári, Dávid
Sápi, Zoltán
author_sort Sápi, Johanna
collection PubMed
description BACKGROUND: Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated different methods to find the best tumor volume estimation since it creates the possibility for precise and effective drug administration with a much lower dose than in the protocol. MATERIALS AND METHODS: We have examined C38 mouse colon adenocarcinoma and HT-29 human colorectal adenocarcinoma. In both cases, three groups were compared in the experiments. The first group did not receive therapy, the second group received one 200 μg bevacizumab dose for a treatment period (protocol-based therapy), and the third group received 1.1 μg bevacizumab every day (quasi-continuous therapy). Tumor volume measurement was performed by digital caliper and small animal MRI. The mathematical relationship between MRI-measured tumor volume and mass was investigated to estimate accurate tumor volume using caliper-measured data. A two-dimensional mathematical model was applied for tumor volume evaluation, and tumor- and therapy-specific constants were calculated for the three different groups. The effectiveness of bevacizumab administration was examined by statistical analysis. RESULTS: In the case of C38 adenocarcinoma, protocol-based treatment did not result in significantly smaller tumor volume compared to the no treatment group; however, there was a significant difference between untreated mice and mice who received quasi-continuous therapy (p = 0.002). In the case of HT-29 adenocarcinoma, the daily treatment with one-twelfth total dose resulted in significantly smaller tumors than the protocol-based treatment (p = 0.038). When the tumor has a symmetrical, solid closed shape (typically without treatment), volume can be evaluated accurately from caliper-measured data with the applied two-dimensional mathematical model. CONCLUSION: Our results provide a theoretical background for a much more effective bevacizumab treatment using optimized administration.
format Online
Article
Text
id pubmed-4635016
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46350162015-11-13 Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy Sápi, Johanna Kovács, Levente Drexler, Dániel András Kocsis, Pál Gajári, Dávid Sápi, Zoltán PLoS One Research Article BACKGROUND: Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated different methods to find the best tumor volume estimation since it creates the possibility for precise and effective drug administration with a much lower dose than in the protocol. MATERIALS AND METHODS: We have examined C38 mouse colon adenocarcinoma and HT-29 human colorectal adenocarcinoma. In both cases, three groups were compared in the experiments. The first group did not receive therapy, the second group received one 200 μg bevacizumab dose for a treatment period (protocol-based therapy), and the third group received 1.1 μg bevacizumab every day (quasi-continuous therapy). Tumor volume measurement was performed by digital caliper and small animal MRI. The mathematical relationship between MRI-measured tumor volume and mass was investigated to estimate accurate tumor volume using caliper-measured data. A two-dimensional mathematical model was applied for tumor volume evaluation, and tumor- and therapy-specific constants were calculated for the three different groups. The effectiveness of bevacizumab administration was examined by statistical analysis. RESULTS: In the case of C38 adenocarcinoma, protocol-based treatment did not result in significantly smaller tumor volume compared to the no treatment group; however, there was a significant difference between untreated mice and mice who received quasi-continuous therapy (p = 0.002). In the case of HT-29 adenocarcinoma, the daily treatment with one-twelfth total dose resulted in significantly smaller tumors than the protocol-based treatment (p = 0.038). When the tumor has a symmetrical, solid closed shape (typically without treatment), volume can be evaluated accurately from caliper-measured data with the applied two-dimensional mathematical model. CONCLUSION: Our results provide a theoretical background for a much more effective bevacizumab treatment using optimized administration. Public Library of Science 2015-11-05 /pmc/articles/PMC4635016/ /pubmed/26540189 http://dx.doi.org/10.1371/journal.pone.0142190 Text en © 2015 Sápi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sápi, Johanna
Kovács, Levente
Drexler, Dániel András
Kocsis, Pál
Gajári, Dávid
Sápi, Zoltán
Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
title Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
title_full Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
title_fullStr Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
title_full_unstemmed Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
title_short Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
title_sort tumor volume estimation and quasi-continuous administration for most effective bevacizumab therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635016/
https://www.ncbi.nlm.nih.gov/pubmed/26540189
http://dx.doi.org/10.1371/journal.pone.0142190
work_keys_str_mv AT sapijohanna tumorvolumeestimationandquasicontinuousadministrationformosteffectivebevacizumabtherapy
AT kovacslevente tumorvolumeestimationandquasicontinuousadministrationformosteffectivebevacizumabtherapy
AT drexlerdanielandras tumorvolumeestimationandquasicontinuousadministrationformosteffectivebevacizumabtherapy
AT kocsispal tumorvolumeestimationandquasicontinuousadministrationformosteffectivebevacizumabtherapy
AT gajaridavid tumorvolumeestimationandquasicontinuousadministrationformosteffectivebevacizumabtherapy
AT sapizoltan tumorvolumeestimationandquasicontinuousadministrationformosteffectivebevacizumabtherapy